133446-99-8

Basic information

• Product Name: 2-BROMOMETHYL-4-NITRO-BENZOIC ACID METHYL ESTER
• Synonyms: 2-BROMOMETHYL-4-NITRO-BENZOIC ACID METHYL ESTER;Methyl 2-(broMoMethyl)-4-nitrobenzoate;Lenalidomide Impurity 16
• CAS NO: 133446-99-8
• Molecular Formula: C₉H₈BrNO₄
• Molecular Weight: 274.08
• Mol File: 133446-99-8.mol

Chemical Properties

• Boiling Point: 398.4±37.0 °C(Predicted)
• Appearance: /
• Density: 1.624±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-BROMOMETHYL-4-NITRO-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMOMETHYL-4-NITRO-BENZOIC ACID METHYL ESTER(133446-99-8)
• EPA Substance Registry System: 2-BROMOMETHYL-4-NITRO-BENZOIC ACID METHYL ESTER(133446-99-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-43
• Safety Statements: 36/37
• Hazardous Substances Data: 133446-99-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-BROMOMETHYL-4-NITRO-BENZOIC ACID METHYL ESTER is used as a synthetic intermediate for the preparation of cyclic hydroxamic acid derivatives. These derivatives exhibit histone deacetylase inhibitory activity, which is a promising approach for the development of antitumor agents. By modulating the activity of histone deacetylases, these compounds can interfere with the regulation of gene expression, leading to the suppression of tumor growth and progression.

Upstream product

• 62621-09-4 methyl 2-methyl-4-nitrobenzoate 
• 1975-51-5 2-methyl-4-nitrobenzoic acid 
• 99584-16-4 2-methyl-4-nitro-benzoic acid amide 
• 89001-53-6 2-cyano-5-nitrotoluene 
• 99-52-5 2-methyl-4-nitro-benzenamine 
• 99548-55-7 4-bromo-2-methyl-benzoic acid methyl ester 

Downstream Products

• 246545-29-9 methyl 2-L-(2,3-dihydro-5-nitro-1-oxo-2(1H)-isoindolyl)-5-[N-(benzyloxycarbonyl)amino]pentanoate 
• 807343-00-6 2-benzyl-5-nitroisoindolin-1-one 
• 924266-46-6 4-nitro-2-phenoxymethyl-benzoic acid methyl ester 
• 915034-91-2 4-nitro-2-(phenoxymethyl)benzoic acid 
• 915034-92-3 8-(2-nitrophenylamino)-6H-dibenzo[b,e]oxepin-11-one 
• 924266-47-7 8-(4-nitrophenylamino)-6H-dibenzo[b,e]oxepin-11-one 
• 924266-51-3 8-(2-fluoro-4-nitrophenylamino)-6H-dibenzo[b,e]oxepin-11-one 
• 914646-60-9 5-amino-2-benzylisoindolin-1-one 
• 914646-62-1 (E)-methyl 3-(2-benzyl-1-oxoisoindolin-5-yl)acrylate 
• 914646-63-2 (E)-3-(2-benzyl-1-oxoisoindolin-5-yl)acrylic acid 
• 914646-61-0 methyl 3-(2-benzyl-1-oxoisoindolin-5-yl)-2-bromopropanoate 
• 914646-64-3 (E)-3-(2-benzyl-1-oxoisoindolin-5-yl)-N-(tetrahydro-2H-pyran-2-yloxy)acrylamide 
• 246545-30-2 methyl 2-L-(5-amino-2,3-dihydro-1-oxo-2(1H)-isoindolyl)-5-[N-(benzyloxycarbonyl)amino]pentanoate 
• 246545-31-3 2-{5-[(2-acetylamino-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-6-ylmethyl)-formyl-amino]-1-oxo-1,3-dihydro-isoindol-2-yl}-5-benzyloxycarbonylamino-pentanoic acid methyl ester 

Relevant articles and documents

Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer

Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3–fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.

Influence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands

Proteolysis targeting chimeras (PROTACs) hijacking the cereblon (CRBN) E3 ubiquitin ligase have emerged as a novel paradigm in drug development. Herein we found that linker attachment points of CRBN ligands highly affect their aqueous stability and neosubstrate degradation features. This work provides a blueprint for the assembly of future heterodimeric CRBN-based degraders with tailored properties.

COMPOUNDS AND USES THEREOF

The present disclosure features compounds and methods useful for the treatment of BAF complex-related disorders.

Development of Novel Isoindolone-Based Compounds against Trypanosoma brucei rhodesiense

This study identified the isoindolone ring as a scaffold for novel agents against Trypanosoma brucei rhodesiense and explored the structure-activity relationships of various aromatic ring substitutions. The compounds were evaluated in an integrated in vit

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF

Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer 5 or a metabolic disease.

Pyridazine-3-carboxamide compound and preparation method and application thereof in medicine

The invention relates to a pyridazine-3-carboxamide compound suitable for inhibiting or regulating Janus kinase (JAK), especially tyrosine kinase 2 (TYK2), a preparation method of the pyridazine-3-carboxamide compound and an application of the pyridazine-3-carboxamide compound in medicine. Specifically, the invention relates to a compound represented by a general formula (I) and pharmaceutically acceptable salts thereof, a pharmaceutical composition containing the compound or the pharmaceutically acceptable salts thereof, and a method for treating and/or preventing Janus kinase-mediated related diseases, especially autoimmune diseases, inflammatory diseases and cancer by applying the compound or the pharmaceutically acceptable salts thereof, and a preparation method of the compound or thepharmaceutically acceptable salts thereof. Each substituent of the general formula (I) has the same definition as in the specification.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Linker Variation and Structure-Activity Relationship Analyses of Carboxylic Acid-based Small Molecule STAT3 Inhibitors

The molecular determinants for the activities of the reported benzoic acid (SH4-54), salicylic acid (BP-1-102), and benzohydroxamic acid (SH5-07)-based STAT3 inhibitors were investigated to design optimized analogues. All three leads are based on an N-met

2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS

The present disclosure provides pharmaceutical compositions comprising 2-arylsulfonamido-N-arylacetamide derivatized Stat3 inhibitors and certain pharmaceutically acceptable salts thereof, and methods of their use.